National Eating Disorders Awareness Week 2026: R&D Opportunities in Biotech and Pharma
NEDAW 2026 Context
NEDAW 2026 highlights eating disorders’ effects, particularly on women and girls. A 2025 trial at Orygen tested high-definition transcranial direct current stimulation (HD-tDCS) on eight women with AN. Three-quarters showed reduced symptoms and improved body mass index. Eating disorders carry elevated mortality risk.
Approved Treatments
Fluoxetine is FDA-approved for BN. Lisdexamfetamine is FDA-approved for moderate to severe BED in adults. No FDA-approved pharmacologic treatment exists for AN.
| Condition | Approved Medication | Regulatory Status |
| Bulimia nervosa | Fluoxetine | FDA-approved for acute and maintenance |
| Binge-eating disorder | Lisdexamfetamine | FDA-approved for moderate to severe in adults |
| Anorexia nervosa | None | No FDA-approved pharmacologic treatment |
Drug Discovery Targets
Clearmind Medicine filed an international patent application in April 2025 for 3-MMC combined with PEA for AN and BN. Psilocybin trials include five registered post-2020, with completed studies pending data release. UCSF trials in 2026 test psilocybin for refractory AN. Leptin receptor agonists target atypical AN (WO2025061871A1). Non-hallucinogenic 5-HT2A agonists address eating disorders (WO2025122964A1). Shortwave Pharma develops psilocybin for eating disorders.
Preclinical Development
Preclinical work uses activity-based anorexia (ABA) models for weight loss and resilience phenotyping. AI aids risk prediction and data analysis from in vitro and in vivo studies.
| Model/Tech | Application in Eating Disorders | Key Advantage |
| ABA Paradigm | Weight loss/resilience phenotyping | Food anticipatory behavior |
| AI-Driven Screening | Risk prediction | Early intervention |
| Aspect | Traditional Models | AI-Enhanced Models |
| Speed | Months for screening | Days with predictive algorithms |
| Accuracy | Limited by animal variability | Improved via data integration |
| Cost | High due to iterations | Reduced through simulation |
Regulatory Pathways
FDA approves GLP-1s for weight management, not eating disorders. Psychedelics use 505(b)(2) pathways. Devices like HD-tDCS show symptom reduction in AN trials. Neuromodulation approaches follow medical device frameworks.
Manufacturing Considerations
Novel biologics face scale-up issues.
Saturo Global Services
Saturo Global provides data curation and management, indexing and abstracting, strategic patent support, and data visualization.
Conclusion
Eating disorders include anorexia nervosa (AN), bulimia nervosa (BN), and binge-eating disorder (BED). FDA-approved treatments consist of fluoxetine for BN and lisdexamfetamine for BED. No medication is approved for AN. R&D efforts examine novel targets, preclinical models, regulatory pathways, and data management.
National Eating Disorders Awareness Week (NEDAW) which occurs from February 23 to March 1, 2026, underscores limited approved options for eating disorders. Ongoing efforts target novel pathways, apply preclinical models, and address regulatory and data needs. R&D requires structured data management and reproducible analytics.
References
National Eating Disorders Association. 2026. National Eating Disorders Awareness Week. https://www.nationaleatingdisorders.org/nedaw/
Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010–2025). PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12855243/
Artificial Intelligence in Eating Disorder Treatment. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12884252/
Clearmind Medicine Files International Patent Application. 2025. https://news.futunn.com/en/post/56011421/clearmind-medicine-files-international-patent-application-for-novel-treatment-of
Saturo Global Services. 2025. https://saturoglobal.com/services/
Psilocybin in Eating Disorders: Systematic Review. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12307571/
GLP-1 Medications & Eating Disorders. ANAD. 2026. https://anad.org/learning-library/glp-1-medications-eating-disorders/
Rethinking Preclinical Models of Anorexia Nervosa. PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8898221/
Preliminary Trial: Brain Stimulation for Anorexia. 2025. https://www.orygen.org.au/About/News-And-Events/2025/PRELIMINARY-TRIAL-SHOWS-BRAIN-STIMULATION-COULD-OF
Using AI to Advance Eating Disorder Research. PubMed. 2025. https://pubmed.ncbi.nlm.nih.gov/39921480/
WO2025061871A1: Leptin Receptor Agonist for Atypical AN. 2025. https://www.perplexity.ai/rest/file-repository/patents/WO2025061871A1
WO2025122964A1. https://www.perplexity.ai/rest/file-repository/patents/WO2025122964A1
Prospects for new drugs to treat binge-eating disorder. PMC. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9150143/
Phillipou A, et al. 2025. High-definition transcranial direct current stimulation of the inferior parietal lobe in anorexia nervosa. Australian and New Zealand Journal of Psychiatry. https://journals.sagepub.com/doi/10.1177/00048674251362048
Psych Capital. 2023. Psych Capital to acquire Shortwave Pharma. https://psychedelichealth.co.uk/2023/06/19/psych-capital-shortwave-pharma-eating-disorder-treatments
UCSF. 2026. Study of Psilocybin for Anorexia in Young Adults. https://clinicaltrials.ucsf.edu/trial/NCT06399263
